India Considers Price Caps On Medical Devices
This article was originally published in PharmAsia News
Executive Summary
The government is set to gather data on the price, supply and availability of medical devices in India and compare them with other countries in advance of considering price controls. The National Pharmaceutical Pricing Authority has been told to gather the information as part of an effort to set guidelines for negotiations with device makers for a cap on the prices of their new products, both drugs and medical devices, as part of the marketing-approval process. The move is intended to ensure consumers would have access to devices at reasonable prices, according to the government. NPPA has recommended the device price be set according to its type, such as cardiac equipment used in government hospitals. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.